blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3720471

EP3720471 - COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A COPOLYAMINO ACID [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.10.2024
Database last updated on 19.10.2024
FormerThe patent has been granted
Status updated on  27.10.2023
FormerGrant of patent is intended
Status updated on  11.06.2023
FormerExamination is in progress
Status updated on  11.11.2022
FormerRequest for examination was made
Status updated on  11.09.2020
FormerThe international publication has been made
Status updated on  14.06.2019
Formerunknown
Status updated on  10.01.2019
Most recent event   Tooltip18.10.2024Lapse of the patent in a contracting state
New state(s): BE		published on 20.11.2024 [2024/47]
Applicant(s)For all designated states
Adocia
115, Avenue Lacassagne
69003 Lyon / FR
[2020/42]
Inventor(s)01 / CHAN, You-Ping
12 avenue de la Haute Combe
69360 Ternay / FR
02 / GEISSLER, Alexandre
28 rue Camille Roy
69007 Lyon / FR
03 / NOEL, Romain
49 cours Tolstoï
69100 Villeurbanne / FR
04 / CHARVET, Richard
19 rue de la Bièvre
69140 Rillieux La Pape / FR
05 / LAURENT, Nicolas
465 avenue Joséphine Guillon
01700 Miribel / FR
 [2020/42]
Representative(s)Tripoz, Inès
Cabinet Tripoz
Le Pôle Sud
22 rue Seguin
69002 Lyon / FR
[2020/42]
Application number, filing date18826205.907.12.2018
[2020/42]
WO2018EP84065
Priority number, dateFR2017006180907.12.2017         Original published format: FR 1761809
US201762606137P07.12.2017         Original published format: US 201762606137 P
FR2018005593929.06.2018         Original published format: FR 1855939
[2020/42]
Filing languageFR
Procedural languageFR
PublicationType: A1 Application with search report
No.:WO2019110837
Date:13.06.2019
Language:FR
[2019/24]
Type: A1 Application with search report 
No.:EP3720471
Date:14.10.2020
Language:FR
The application published by WIPO in one of the EPO official languages on 13.06.2019 takes the place of the publication of the European patent application.
[2020/42]
Type: B1 Patent specification 
No.:EP3720471
Date:29.11.2023
Language:FR
[2023/48]
Search report(s)International search report - published on:EP13.06.2019
ClassificationIPC:A61K38/26, A61K47/34, A61K9/08, A61P3/10
[2020/42]
CPC:
A61K38/26 (EP,KR,US); A61K9/08 (KR,US); A61K45/06 (KR);
A61K47/02 (US); A61K47/34 (EP,KR,US); A61K9/0019 (EP,KR,US);
A61P3/10 (KR); C08L77/04 (KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/42]
Extension statesBANot yet paid
MENot yet paid
Validation statesKH07.07.2020
MA07.07.2020
TN07.07.2020
TitleGerman:ZUSAMMENSETZUNGEN IN FORM EINER INJIZIERBAREN WÄSSRIGEN LÖSUNG MIT MENSCHLICHEM GLUCAGON UND EINER COPOLYAMINOSÄURE[2020/42]
English:COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A COPOLYAMINO ACID[2020/42]
French:COMPOSITIONS SOUS FORME D'UNE SOLUTION AQUEUSE INJECTABLE COMPRENANT DU GLUCAGON HUMAIN ET UN CO-POLYAMINOACIDE[2020/42]
Entry into regional phase07.07.2020National basic fee paid 
07.07.2020Designation fee(s) paid 
07.07.2020Examination fee paid 
Examination procedure07.07.2020Amendment by applicant (claims and/or description)
07.07.2020Examination requested  [2020/42]
07.07.2020Date on which the examining division has become responsible
15.11.2022Despatch of a communication from the examining division (Time limit: M06)
19.05.2023Reply to a communication from the examining division
12.06.2023Communication of intention to grant the patent
23.10.2023Fee for grant paid
23.10.2023Fee for publishing/printing paid
23.10.2023Receipt of the translation of the claim(s)
Opposition(s)30.08.2024No opposition filed within time limit [2024/45]
Fees paidRenewal fee
26.12.2020Renewal fee patent year 03
29.12.2021Renewal fee patent year 04
30.12.2022Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT29.11.2023
CZ29.11.2023
DK29.11.2023
EE29.11.2023
ES29.11.2023
HR29.11.2023
IT29.11.2023
LT29.11.2023
LV29.11.2023
MC29.11.2023
NL29.11.2023
PL29.11.2023
RO29.11.2023
RS29.11.2023
SE29.11.2023
SK29.11.2023
SM29.11.2023
IE07.12.2023
LU07.12.2023
BE31.12.2023
BG29.02.2024
NO29.02.2024
GR01.03.2024
IS29.03.2024
PT01.04.2024
[2024/47]
Former [2024/46]AT29.11.2023
CZ29.11.2023
DK29.11.2023
EE29.11.2023
ES29.11.2023
HR29.11.2023
IT29.11.2023
LT29.11.2023
LV29.11.2023
MC29.11.2023
NL29.11.2023
PL29.11.2023
RO29.11.2023
RS29.11.2023
SE29.11.2023
SK29.11.2023
SM29.11.2023
IE07.12.2023
LU07.12.2023
BG29.02.2024
NO29.02.2024
GR01.03.2024
IS29.03.2024
PT01.04.2024
Former [2024/40]AT29.11.2023
CZ29.11.2023
DK29.11.2023
EE29.11.2023
ES29.11.2023
HR29.11.2023
IT29.11.2023
LT29.11.2023
LV29.11.2023
MC29.11.2023
NL29.11.2023
PL29.11.2023
RO29.11.2023
RS29.11.2023
SE29.11.2023
SK29.11.2023
SM29.11.2023
LU07.12.2023
BG29.02.2024
NO29.02.2024
GR01.03.2024
IS29.03.2024
PT01.04.2024
Former [2024/36]AT29.11.2023
CZ29.11.2023
DK29.11.2023
EE29.11.2023
ES29.11.2023
HR29.11.2023
IT29.11.2023
LT29.11.2023
LV29.11.2023
NL29.11.2023
PL29.11.2023
RO29.11.2023
RS29.11.2023
SE29.11.2023
SK29.11.2023
SM29.11.2023
BG29.02.2024
NO29.02.2024
GR01.03.2024
IS29.03.2024
PT01.04.2024
Former [2024/35]AT29.11.2023
CZ29.11.2023
DK29.11.2023
EE29.11.2023
ES29.11.2023
HR29.11.2023
LT29.11.2023
LV29.11.2023
NL29.11.2023
PL29.11.2023
RO29.11.2023
RS29.11.2023
SE29.11.2023
SM29.11.2023
BG29.02.2024
NO29.02.2024
GR01.03.2024
IS29.03.2024
Former [2024/34]DK29.11.2023
EE29.11.2023
ES29.11.2023
HR29.11.2023
LT29.11.2023
LV29.11.2023
NL29.11.2023
PL29.11.2023
RS29.11.2023
SE29.11.2023
SM29.11.2023
BG29.02.2024
NO29.02.2024
GR01.03.2024
IS29.03.2024
Former [2024/33]DK29.11.2023
ES29.11.2023
HR29.11.2023
LT29.11.2023
LV29.11.2023
NL29.11.2023
PL29.11.2023
RS29.11.2023
SE29.11.2023
SM29.11.2023
BG29.02.2024
NO29.02.2024
GR01.03.2024
IS29.03.2024
Former [2024/26]ES29.11.2023
HR29.11.2023
LT29.11.2023
LV29.11.2023
NL29.11.2023
PL29.11.2023
RS29.11.2023
SE29.11.2023
BG29.02.2024
NO29.02.2024
GR01.03.2024
IS29.03.2024
Former [2024/25]ES29.11.2023
HR29.11.2023
LT29.11.2023
PL29.11.2023
RS29.11.2023
SE29.11.2023
BG29.02.2024
NO29.02.2024
GR01.03.2024
IS29.03.2024
Former [2024/24]ES29.11.2023
HR29.11.2023
LT29.11.2023
RS29.11.2023
SE29.11.2023
BG29.02.2024
NO29.02.2024
GR01.03.2024
IS29.03.2024
Former [2024/21]LT29.11.2023
BG29.02.2024
GR01.03.2024
IS29.03.2024
Former [2024/20]GR01.03.2024
IS29.03.2024
Cited inInternational search[XA]GB1202607  (NOVO TERAPEUTISK LABOR AS [DK]) [X] 16 * page 2; claims 1,5 * [A] 1-15;
 [A]WO2013104861  (ADOCIA [FR]) [A] 1-15* the whole document *;
 [XP]WO2017211918  (ADOCIA [FR]) [XP] 1-15 * claims 1-16 *
by applicantGB1202607
 FR2801226
 US6384016
 FR2840614
 US2011097386
 WO2011138802
 WO2012059764
 WO2013101749
 WO2014096440
 WO2015095389
 US2015291680
    - ONOUE et al., Pharm. Res., (20040000), vol. 21, no. 7, pages 1274 - 83
    - KIRSH et al., International Journal of Pharmaceutics, (20000000), vol. 203, pages 115 - 125
    - JACKSON et al., Curr. Diab. Rep., (20120000), vol. 12, pages 705 - 710
    - MATILAINEN et al., J. Pharm. Sci, (20080000), vol. 97, pages 2720 - 2729
    - Eur. J. Pharm. Sci., (20090000), vol. 36, pages 412 - 420
    - GARAY et al., Expert Opin Drug Deliv, (20120000), vol. 9, pages 1319 - 1323
    - TAN et al., Diabetes, (20130000), vol. 62, pages 1131 - 138
    - DEMING, T.J., Adv. Polym. Sci., (20060000), vol. 202, pages 1 - 18
    - DEMING, T.J., Nature, (19970000), vol. 390, pages 386 - 389
    - LU H., J. Am. Chem. Soc., (20070000), vol. 129, pages 14114 - 14115
    - LU H., J. Am. Chem. Soc., (20080000), vol. 130, pages 12562 - 12563
    - NAIKI et al., Anal. BioChem., (19890000), vol. 177, pages 244 - 249
    - LEVINE, Methods. Enzymol., (19990000), vol. 309, pages 274 - 284
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.